Objective: To present the experience of managing myomatosis with selective arterial embolization. Material and methods: Observational, cross-sectional, descriptive and prospective study during the period January 2015-December 2019, in patients undergoing selective arterial embolization as a treatment for myomatosis. Clinical characteristics and outcomes of interest were recorded for statistical analysis (age, symptoms, type of fibroids, imaging characteristics, changes in size and severity of symptoms at 6 months). Results: The most frequent clinical manifestations were hyperpolymenorrhea (40.9%), anemia (13.6%), infertility (9.1%) and dyspareunia (9.1%). 68.2% of the fibroids were FIGO 2 (submucosal > 50% intramural), 22.7% FIGO 1 (submucosal <50% intramural) and 9.1% FIGO 5 (subserous > 50% intramural). By T2-weighted MRI, 4.5% were classified as isointense, 9.1% hyperintense, 68.2% heterogeneous, mostly hypointense (hyaline degeneration), and 18.2% heterogeneous mostly hyperintense (cystic degeneration). At 6 months, in 2 patients the size was reduced by 95%, 75% in three, 50% in 16 and 25%. The rate of successful procedures was 95.5% and the intensity of symptoms decreased in all patients more than 90%. Conclusions: The myomatosis was successfully treated with selective arterial embolization, the size of the fibroids and the associated symptoms were reduced.